$37.96
-1.21[-3.09%]
At close: May 17
$37.96
0[0.00%]
After Hours: 4:00PM EDT
Rhythm Pharmaceuticals
(NASDAQ:RYTM)Rhythm Pharmaceuticals Stock (NASDAQ:RYTM), Analyst Ratings, Price Targets, Predictions
Rhythm Pharmaceuticals Inc has a consensus price target of $46.45, established from looking at the 51 latest analyst ratings. The last 3 analyst ratings were released from Canaccord Genuity, B of A Securities, and Needham on May 8, 2024, May 8, 2024, and May 7, 2024. With an average price target of $55.67 between Canaccord Genuity, B of A Securities, and Needham, there's an implied 46.65% upside for Rhythm Pharmaceuticals Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Canaccord Genuity
B of A Securities
Needham
Wells Fargo
Goldman Sachs
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Rhythm Pharmaceuticals
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/08/2024 | Buy Now | 108.11% | Canaccord Genuity | Whitney Ijem | $80 → $79 | Maintains | Buy | Get Alert |
| 05/08/2024 | Buy Now | 10.64% | B of A Securities | Tazeen Ahmad | $49 → $42 | Downgrade | Buy → Neutral | Get Alert |
| 05/07/2024 | Buy Now | 21.18% | Needham | Joseph Stringer | $50 → $46 | Maintains | Buy | Get Alert |
| 04/26/2024 | Buy Now | 31.72% | Needham | Joseph Stringer | → $50 | Reiterates | Buy → Buy | Get Alert |
| 04/18/2024 | Buy Now | 36.99% | Wells Fargo | Derek Archila | $53 → $52 | Maintains | Overweight | Get Alert |
| 04/10/2024 | Buy Now | 31.72% | Needham | Joseph Stringer | → $50 | Reiterates | Buy → Buy | Get Alert |
| 02/22/2024 | Buy Now | 31.72% | Needham | Joseph Stringer | → $50 | Reiterates | Buy → Buy | Get Alert |
| 01/26/2024 | Buy Now | 36.99% | Goldman Sachs | Corinne Jenkins | $42 → $52 | Maintains | Buy | Get Alert |
| 01/26/2024 | Buy Now | 31.72% | Needham | Joseph Stringer | → $50 | Reiterates | Buy → Buy | Get Alert |
| 01/25/2024 | Buy Now | 36.99% | Goldman Sachs | Corinne Jenkins | $42 → $52 | Maintains | Buy | Get Alert |
| 01/04/2024 | Buy Now | 31.72% | Needham | Joseph Stringer | $45 → $50 | Maintains | Buy | Get Alert |
| 12/19/2023 | Buy Now | 44.89% | Morgan Stanley | Jeffrey Hung | $29 → $55 | Upgrade | Equal-Weight → Overweight | Get Alert |
| 12/19/2023 | Buy Now | 39.62% | Wells Fargo | Derek Archila | $48 → $53 | Maintains | Overweight | Get Alert |
| 12/07/2023 | Buy Now | 10.64% | Goldman Sachs | Corinne Jenkins | $38 → $42 | Maintains | Buy | Get Alert |
| 12/07/2023 | Buy Now | 18.55% | Needham | Joseph Stringer | $32 → $45 | Maintains | Buy | Get Alert |
| 11/08/2023 | Buy Now | 5.37% | Wells Fargo | Derek Archila | $38 → $40 | Maintains | Overweight | Get Alert |
| 10/10/2023 | Buy Now | -23.6% | Morgan Stanley | Jeffrey Hung | $28 → $29 | Maintains | Equal-Weight | Get Alert |
| 08/02/2023 | Buy Now | -26.24% | Morgan Stanley | Jeffrey Hung | $28 → $28 | Reiterates | Equal-Weight → Equal-Weight | Get Alert |
| 08/02/2023 | Buy Now | -28.87% | B of A Securities | Tazeen Ahmad | $22 → $27 | Upgrade | Neutral → Buy | Get Alert |
| 08/02/2023 | Buy Now | -15.7% | Needham | Joseph Stringer | → $32 | Reiterates | Buy → Buy | Get Alert |
| 06/20/2023 | Buy Now | -15.7% | Needham | Joseph Stringer | → $32 | Reiterates | Buy → Buy | Get Alert |
| 04/18/2023 | Buy Now | -15.7% | Needham | Joseph Stringer | → $32 | Reiterates | → Buy | Get Alert |
| 03/02/2023 | Buy Now | -26.24% | Morgan Stanley | Jeffrey Hung | $26 → $28 | Maintains | Equal-Weight | Get Alert |
| 03/02/2023 | Buy Now | 47.52% | Canaccord Genuity | Whitney Ijem | $52 → $56 | Maintains | Buy | Get Alert |
| 03/02/2023 | Buy Now | 18.55% | Goldman Sachs | Corinne Jenkins | $40 → $45 | Maintains | Buy | Get Alert |
| 03/02/2023 | Buy Now | -7.8% | Ladenburg Thalmann | Michael Higgins | → $35 | Reiterates | → Buy | Get Alert |
| 03/02/2023 | Buy Now | -15.7% | Needham | Joseph Stringer | → $32 | Reiterates | → Buy | Get Alert |
| 01/26/2023 | Buy Now | 5.37% | Goldman Sachs | Corinne Jenkins | $35 → $40 | Maintains | Buy | Get Alert |
| 01/18/2023 | Buy Now | — | Canaccord Genuity | Whitney Ijem | — | Assumes | → Buy | Get Alert |
| 11/10/2022 | Buy Now | -7.8% | Goldman Sachs | Graig Suvannavejh | $31 → $35 | Maintains | Buy | Get Alert |
FAQ
What is the target price for Rhythm Pharmaceuticals (RYTM)?
The latest price target for Rhythm Pharmaceuticals (NASDAQ: RYTM) was reported by Canaccord Genuity on May 8, 2024. The analyst firm set a price target for $79.00 expecting RYTM to rise to within 12 months (a possible 108.11% upside). 21 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Rhythm Pharmaceuticals (RYTM)?
The latest analyst rating for Rhythm Pharmaceuticals (NASDAQ: RYTM) was provided by Canaccord Genuity, and Rhythm Pharmaceuticals maintained their buy rating.
When was the last upgrade for Rhythm Pharmaceuticals (RYTM)?
The last upgrade for Rhythm Pharmaceuticals Inc happened on December 19, 2023 when Morgan Stanley raised their price target to $55. Morgan Stanley previously had an equal-weight for Rhythm Pharmaceuticals Inc.
When was the last downgrade for Rhythm Pharmaceuticals (RYTM)?
The last downgrade for Rhythm Pharmaceuticals Inc happened on May 8, 2024 when B of A Securities changed their price target from $49 to $42 for Rhythm Pharmaceuticals Inc.
When is the next analyst rating going to be posted or updated for Rhythm Pharmaceuticals (RYTM)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Rhythm Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Rhythm Pharmaceuticals was filed on May 8, 2024 so you should expect the next rating to be made available sometime around May 8, 2025.
Is the Analyst Rating Rhythm Pharmaceuticals (RYTM) correct?
While ratings are subjective and will change, the latest Rhythm Pharmaceuticals (RYTM) rating was a maintained with a price target of $80.00 to $79.00. The current price Rhythm Pharmaceuticals (RYTM) is trading at is $37.96, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.